IQ2™ Applications - Emergency Department

Applications & Outcomes in the Emergency Department & 23-Hour Observation Units
The IQ2™ provides unique real-time cardiac, hemodynamic and pulmonary data that will enable improved patient outcomes while enhancing ED operations and improving both hospital and physician revenues.

When used to monitor hemodynamic changes continuously during treatment, the IQ2™ provides real-time data with which the physician can interact to support his decisions regarding therapeutic interventions and drug titration aggressiveness with objective, defensible data.

The IQ2™ attaches to the patient though the use of electrodes and is generally a 5-minute procedure, usually undertaken by a nurse or an ECG technician. During set-up, the operator must place electrodes in correct positions, take a single measurement (no. of inches between electrodes) and enter patient data into the monitor. The assessment process itself then takes between 2 to 5 minutes, depending on the data desired.

Generally, only one set up is required for each patient stay while in the ED. As the patient is treated, re-assessment will be made by the physician periodically to determine effectiveness of treatment. For CHF, this could be three or more times over the course of a 4 - 23 hour stay. The IQ2™ can be disconnected from the patient and reconnected later utilizing the same electrode set left in place.

Examples of the IQ2™'s Use in the Hospital ED and 23-Hour Observation Unit:

  • To make an immediate differential diagnosis whether a patient who is presenting with dypsnea, sweating, and/or high pulse rate has Congestive Heart Failure exacerbation or is suffering from a respiratory ailment.
  • To determine degree of pulmonary edema upon presentation ("wet or dry") and to monitor change in degree of edema as therapy undertaken; to determine need for and progress of diuresis and to provide data supporting titration with optimal aggressiveness.
  • To titrate diuretics, beta blockers, vasodilators and ACE inhibitors; to monitor effectiveness of inotropic therapy and sublingual nitroglycerin. The IQ2™ supports optimal aggressiveness based on objective, reproducible and defensible data.
  • To determine whether patients with a variety of presenting conditions are dehydrated, hypovolemic (volume depleted) or volume overloaded.
  • To provide objective data with which to manage infusion rates for blood products.
  • To determine the degree of circulatory derangement or insufficiency which indicates impending shock well in advance of a sharp drop in blood pressure confirming shock.

Demonstrated Outcomes Using the IQ2™'s Data in the ED:

  • To promptly distinguish primary cardiac from pulmonary causes of shortness of breath. The IQ2™ significantly decreases the time needed for ED physicians to make a differential diagnosis of CHF (vs. COPD, pneumonia or other respiratory distress) and initiate appropriate therapy.
  • To increase significantly the number of CHF patients that can be discharged to home or to a CHF observation/intervention unit and then to home.
  • To impact significantly the time needed for physicians to determine whether a CHF patient should be admitted immediately to a hospital inpatient unit, whether the patient is stable enough to be admitted to a step-down unit instead of the CCU, or whether there is significant likelihood that the patient can be stabilized in the hospital
Company | Products | Patient Monitoring | Clinical Trials | Corporate Relations | Abstract/Case Studies | News | Contact
©2008, All Rights Reserved, NMT, Inc. | ETag™, IQ2™ and NcIQ™ are not yet FDA approved for sale